Suppr超能文献

甲状旁腺功能减退症

Hypoparathyroidism.

作者信息

Breslau N A, Pak C Y

出版信息

Metabolism. 1979 Dec;28(12):1261-76. doi: 10.1016/0026-0495(79)90141-0.

Abstract

Recent advances in our understanding of the physiologic actions of PTH and vitamin D have clarified certain aspects of the pathogenesis, classification, and management of hypoparathyroidism. Central to pathogenesis and categorization is the recognition that hypoparathyroidism may result from PTH deficiency, ineffectiveness, or resistance, with a resultant inability to stimulate adenylate cyclase in target tissues. This aberration in adenylate cyclase activity impairs certain physiologic responses such as renal phosphate excretion and renal calcium reabsorption that are required for proper calcium homeostasis. Also critical is the subnormal production of 1 alpha,25-dihydroxycholecalciferol (1,25-DHCC). Although the precise mechanism for the deficiency of 1,25-DHCC remains unclear, one may hypothesize that in hormone-deficient or hormone-ineffective hypoparathyroidism, decreased synthesis results from the absence of the two recognized stimuli for 1 alpha-hydroxylase--bioactive PTH and hypophosphatemia. Provision of either one of these stimuli would then be expected to restore 1,25-DHCC to normal levels, which could explain the calcemic response to PTH in these patients. There is some evidence that the synthesis of 1,25-DHCC may be "primarily" affected in PTH-resistant hypoparathyroidism, and thus may be unresponsive to any of the known stimuli. It remains conceivable, however, that during normocalcemic phases, such patients may improve their renal cyclic AMP and phosphaturic responses to PTH, with associated improvement in 1,25-DHCC synthesis. Certain acquired forms of PTH resistance such as hypomagnesemia and end-stage renal disease may also be associated with defective 1-hydroxylation. Whether occurring primarily or as a secondary process, the subnormal production of 1,25-DHCC may influence calcium and skeletal metabolism directly or by modifying response to PTH. The availability of 1,25-DHCC provides an effective and physiologically meaningful mode of therapy for most cases of hypoparathyroidism.

摘要

我们对甲状旁腺激素(PTH)和维生素D生理作用的最新认识进展,已阐明了甲状旁腺功能减退症发病机制、分类及管理的某些方面。发病机制和分类的核心在于认识到甲状旁腺功能减退症可能源于PTH缺乏、无效或抵抗,导致无法刺激靶组织中的腺苷酸环化酶。腺苷酸环化酶活性的这种异常损害了某些生理反应,如维持正常钙稳态所需的肾磷酸盐排泄和肾钙重吸收。1α,25 - 二羟胆钙化醇(1,25 - DHCC)生成不足也很关键。虽然1,25 - DHCC缺乏的确切机制尚不清楚,但可以推测,在激素缺乏或激素无效的甲状旁腺功能减退症中,合成减少是由于缺乏两种公认的1α - 羟化酶刺激物——生物活性PTH和低磷血症。提供这两种刺激物中的任何一种都有望使1,25 - DHCC恢复到正常水平,这可以解释这些患者对PTH的血钙反应。有证据表明,在PTH抵抗性甲状旁腺功能减退症中,1,25 - DHCC的合成可能“主要”受到影响,因此可能对任何已知刺激均无反应。然而,可以想象,在血钙正常阶段,此类患者可能改善其肾环磷酸腺苷(cAMP)和对PTH的磷尿反应,并伴随1,25 - DHCC合成的改善。某些获得性PTH抵抗形式,如低镁血症和终末期肾病,也可能与1 - 羟化缺陷有关。无论主要发生还是作为继发过程,1, . 25 - DHCC生成不足可能直接影响钙和骨骼代谢或通过改变对PTH的反应来影响。1,25 - DHCC的可用性为大多数甲状旁腺功能减退症病例提供了一种有效且具有生理意义的治疗方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验